Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.7
SANGAMO THERAPEUTICS, INC issued 23,809,523 shares of common stock of warrant to investor in the Offering for reduced from $1.00 to $0.4719.
- Security
- warrant
- Shares
- 23,809,523 shares of common stock
- Purchaser
- investor in the Offering
- Consideration
- reduced from $1.00 to $0.4719
Exact text from the filing
“Purchase Warrants” and together with the Pre-Funded Warrants, the “Warrants”). The combined offering price of each share of Common Stock and accompanying Purchase Warrant is $0.4719. The combined offering price of each Pre-Funded Warrant and accompanying Purchase Warrant is $0.4619. The Common Stock and Pre-Funded Warrants are being sold in combination with
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
- Value
- approximately $25.0 million
- Effective
- 2026-02-03
Exact text from the filing
On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
View on SEC.gov